🔗 Share this article

As America proceeds with historic changes to its vaccine schedules, one figure appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccines during the pandemic and has zeroed in on alleged deaths after Covid vaccination in her brief position at the FDA.

Proposed Overhauls to Childhood Immunization Program

Agency leaders had intended to reveal radical revisions to the childhood vaccine schedule earlier this month, bringing the US with Denmark’s vaccine program, sources say – a major change that would place the US out of step with many the world with little proof for public health gain. The announcement has been delayed until the coming year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to address the audience at the meeting. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth appointee to lead the division this year.

Consolidating Power at the Agency

This interim role might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has often pushed for ending some pediatric vaccine recommendations in the US in order to be more in line with Denmark's approach, a society with universal health coverage and a citizenry about the size of Wisconsin’s.

To date statements, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Expertise

The appointee has no apparent track record in medication creation, regulation or leadership, which has been typical for former directors of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in leading a large organization. She has no expertise in drug approvals.”

Former heads of CBER would “understand legal statutes and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she has not acquired the kind of background that former directors who headed CBER have had.”

The drug center has an enormous workload at the FDA, she stated.

“Many people just focuses on the new drug program, but the generic drug division authorizes thousands of generic drugs. There is also a biosimilars program, over-the-counter program and so forth, and every single one have to be looked after,” Dr. Woodcock said. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a major management aspect to the job, which manages in excess of 5,000 personnel. “It’s a enormous administrative position, if you perform it correctly,” Woodcock concluded.

Response and Controversial Programs

When asked about concerns about Dr. Høeg's fitness for the role and whether this appointment signifies increased cooperation among regulatory chiefs on immunizations, a representative said that the “questions are based on flawed assumptions”.

“This background is consistent with the responsibilities of her job,” the representative stated, pointing to the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg inherits the commissioner’s recently launched priority voucher program, a disputed expedited medication authorization process that allegedly troubled her preceding directors. “By what process are these medications being chosen for this voucher program? Who takes the choices?” Howard asked. “There is a lot of secrecy happening at the regulatory body right now.”

In general, he said, “the FDA appears to be shifting towards less stringent oversight of pharmaceuticals, aside from vaccines.”

Documented Track Record on Immunizations

Concerning immunizations, Høeg has a clearer, if concerning, history, some experts said. She published a research paper using unverified crowd-sourced reports to assess the frequency of myocarditis following Covid vaccination. She advised the state of Florida top health official Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “policy goals” for the new federal leadership included revising rules for new vaccines and ending “optional” immunizations, she stated after the election on a online show. At the agency, Dr. Høeg has according to sources floated the idea of preventing young men from obtaining COVID-19 vaccinations.

“She is an thorough true believer who begins with her preconceived notions and reverse-engineers to retrofit the data in a extremely misleading, untruthful manner,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of other contrarians, {like|